ITMI20032473A1 - DRUG DRUGS CONTAINING A THYOTROPY SALT AND SALMETEROL XINAFOATE - Google Patents

DRUG DRUGS CONTAINING A THYOTROPY SALT AND SALMETEROL XINAFOATE

Info

Publication number
ITMI20032473A1
ITMI20032473A1 IT002473A ITMI20032473A ITMI20032473A1 IT MI20032473 A1 ITMI20032473 A1 IT MI20032473A1 IT 002473 A IT002473 A IT 002473A IT MI20032473 A ITMI20032473 A IT MI20032473A IT MI20032473 A1 ITMI20032473 A1 IT MI20032473A1
Authority
IT
Italy
Prior art keywords
thyotropy
salt
salmeterol xinafoate
drugs containing
drug drugs
Prior art date
Application number
IT002473A
Other languages
Italian (it)
Inventor
Hagen Graebner
Mareke Hartig
Peter Sieger
Rainer Soyka
Michael Trunk
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI20032473(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ITMI20032473A1 publication Critical patent/ITMI20032473A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT002473A 2002-12-20 2003-12-16 DRUG DRUGS CONTAINING A THYOTROPY SALT AND SALMETEROL XINAFOATE ITMI20032473A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20

Publications (1)

Publication Number Publication Date
ITMI20032473A1 true ITMI20032473A1 (en) 2004-06-21

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002473A ITMI20032473A1 (en) 2002-12-20 2003-12-16 DRUG DRUGS CONTAINING A THYOTROPY SALT AND SALMETEROL XINAFOATE

Country Status (21)

Country Link
EP (1) EP1581198A1 (en)
JP (1) JP2006516135A (en)
KR (1) KR20050086930A (en)
CN (1) CN1728988B (en)
AU (1) AU2003288226B2 (en)
BR (1) BR0317443A (en)
CA (1) CA2510779A1 (en)
DE (1) DE10351663A1 (en)
EA (1) EA010588B1 (en)
EC (1) ECSP055855A (en)
FR (1) FR2848849B1 (en)
HR (1) HRP20050570A2 (en)
IT (1) ITMI20032473A1 (en)
MX (1) MXPA05006519A (en)
NO (1) NO20053548L (en)
NZ (1) NZ541303A (en)
PL (1) PL376231A1 (en)
RS (1) RS20050484A (en)
UA (1) UA83813C2 (en)
WO (1) WO2004058233A1 (en)
ZA (1) ZA200503692B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
JP4342426B2 (en) * 2004-11-24 2009-10-14 科研製薬株式会社 Itraconazole formulation for oral administration
CA2617897A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
PL2123650T3 (en) 2005-12-19 2012-09-28 Sicor Inc Novel form of tiotropium bromide and process for preparation thereof
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
DE102007036411A1 (en) 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg powder inhaler
PE20090907A1 (en) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int NEW POWDER DRUGS CONTAINING THOTROPE AND SALMETEROL, AS WELL AS LACTOSE AS AN EXCIPIENT
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (en) 2008-12-23 2015-11-21 Boehringer Ingelheim Int Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
JP2013512229A (en) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of diabetic patients whose genotype has been identified with DDP-IV inhibitors such as linagliptin
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (en) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Diabetes therapy.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR101748796B1 (en) * 2015-09-30 2017-06-19 한미약품 주식회사 Inhalation capsule with enhanced delivery rate of active ingredients
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
WO2020102270A1 (en) * 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations of influenza therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
CN1056974C (en) * 1992-02-11 2000-10-04 格拉克索公司 Drug material suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts
DE10104367A1 (en) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions containing betamimetics with fewer side effects
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
US20040244794A1 (en) * 2001-08-09 2004-12-09 Richards David Hugh Inhalation device with a pharmaceutical composition
WO2003024452A1 (en) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicaments for inhalation

Also Published As

Publication number Publication date
FR2848849B1 (en) 2007-01-05
NO20053548L (en) 2005-09-02
CN1728988B (en) 2010-04-28
WO2004058233A1 (en) 2004-07-15
AU2003288226A1 (en) 2004-07-22
NZ541303A (en) 2008-11-28
KR20050086930A (en) 2005-08-30
CA2510779A1 (en) 2004-07-15
ZA200503692B (en) 2006-10-25
MXPA05006519A (en) 2005-08-26
EA200500902A1 (en) 2006-02-24
EP1581198A1 (en) 2005-10-05
EA010588B1 (en) 2008-10-30
PL376231A1 (en) 2005-12-27
HRP20050570A2 (en) 2006-07-31
JP2006516135A (en) 2006-06-22
BR0317443A (en) 2005-11-16
UA83813C2 (en) 2008-08-26
DE10351663A1 (en) 2004-07-01
ECSP055855A (en) 2005-11-22
FR2848849A1 (en) 2004-06-25
RS20050484A (en) 2007-11-15
CN1728988A (en) 2006-02-01
AU2003288226B2 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
ITMI20032473A1 (en) DRUG DRUGS CONTAINING A THYOTROPY SALT AND SALMETEROL XINAFOATE
CY2011003I1 (en) PHARMACEUTICAL PRODUCTS IN SOLUTION CONTAINING ANTIBODY
NO20055173D0 (en) Pharmaceutical combination combination comprising modafinil and another drug
DK1545662T3 (en) drug delivery
IS7946A (en) drugs
EP1682538A4 (en) Biaryl linked hydroxamates: preparation and pharmaceutical applications
PL359321A1 (en) New salt perindopryl and pharmaceutical composunds containing it
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
DK2266650T3 (en) A drug
NO20054681D0 (en) Pharmaceutical products
DE602004026719D1 (en) ABOUT TABLET
EP1898922A4 (en) Improved drug or pharmaceutical compounds and a preparation thereof
DE50014244D1 (en) PHARMACEUTICAL TRAMADOL SALTS
DK1562573T3 (en) Pharmaceutical pellets comprising tamsulosin and a process for their preparation
ZA200602260B (en) A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug
ZA200701059B (en) Pharmaceutical dosage forms comprising a low-solubllity drug and a polymer
DE602004016967D1 (en) LIQUID PHARMACEUTICAL PALONETONE FORMULATIONS
PL1802329T3 (en) A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
ATE551051T1 (en) ORAL DRUG DELIVERY SYSTEM
ATE434435T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING MODAFINIL
FR2870539B1 (en) NEW METHODS AND MEDICINES
DK1849468T3 (en) Pharmaceutical composition comprising roflumilast and levocetirizine
IL172250A0 (en) Improved pharmaceutical drug candidates and methods for preparation thereof
ITFI20050247A1 (en) A GUIDING SYSTEM FOR MUSEUMS, FAIRS OR EXHIBITIONS IN GENERAL AND A RELATED INFORMATION PROCEDURE
ZA200406881B (en) Medicaments containing betamimetic drugs and a novel anticholineterase drug